Skip to main content

Articles

ACR 2017, Conference Correspondent

Efficacy and Safety of Switching from Adalimumab to Sarilumab in Open-Label Extension of MONARCH Trial in Patients with Active RA

ACR 2017, Conference Correspondent

Improvements in PROs with Tofacitinib with and without MTX versus Adalimumab with MTX for the Treatment of RA

ACR 2017, Conference Correspondent

Sustained Response Following Discontinuation of MTX in Subcutaneous Tocilizumab-Treated Patients with RA

ACR 2017, Conference Correspondent

Longer Duration of Response in MOBILITY Study with Sarilumab plus MTX in Patients with Active, Moderate-to-Severe RA

ACR 2017, Conference Correspondent

Cost per Response for Abatacept versus Adalimumab in Patients with Seropositive, Erosive Early RA

ACR 2017, Conference Correspondent

Long-Term Efficacy and Safety Results of SIRROUND-D Trial of Sirukumab in Patients with Active RA Despite DMARD Treatment

ACR 2017, Conference Correspondent

Upadacitinib (ABT-494) Is Effective in Patients with Active RA with Inadequate Response to Conventional Synthetic DMARDs

ACR 2017, Conference Correspondent

Sarilumab plus DMARDs Lower HbA1c in Diabetic and Nondiabetic Patients with Rheumatoid Arthritis

ACR 2017, Conference Correspondent

Highly Sensitive Cardiac Troponin I Levels in Peripheral Blood Predict CV Events in Patients with RA

Cost per Effectively Treated Patient with Sarilumab for Active, Moderate-to-Severe RA

Page 80 of 244
Results 791 - 800 of 2439